Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study predicted that key components of Platycladi Cacumen, such as quercetin and apigenin, may have stable binding interactions with targets involved in androgenetic alopecia.

This study observed that patients with severe alopecia areata treated with baricitinib experienced increases in total cholesterol, LDL-C, and HDL-C, consistent with a JAK inhibitor class effect, but the mean increase was modest and lipid-lowering medication initiation was infrequent.

This study reports that the newly optimized AR antagonist 39 demonstrated effective hair growth and safety in a mouse model of androgenetic alopecia, showing comparable efficacy to pyrilutamide with faster response and favorable pharmacokinetics, due to innovative structural design and dual metabolic inactivation strategy.

This study found that the methanolic heartwood extract of Avicennia marina significantly inhibits 5α-reductase type 1, reducing 5α-DHT production by 52% in a cell-based assay with human hair dermal papilla cells.

This study found that the CDK4/6 inhibitor palbociclib may protect human hair follicles from the damaging effects of taxane chemotherapy by inducing G1 arrest in stem/progenitor cells.

This study found that the optimized AR antagonist candidate 39, in a hair-growth mouse model, achieved similar efficacy to pyrilutamide with faster onset and favorable safety, suggesting a promising approach for developing topical treatments with low systemic toxicity for androgenetic alopecia.

This study found that a regimen combining cyproterone acetate and testosterone buciclate induced reversible azoospermia in bonnet monkeys, highlighting its potential as an effective male contraceptive.

In this study, baricitinib was evaluated for its effectiveness in promoting concurrent regrowth of scalp hair, eyebrows, and eyelashes in patients with severe alopecia areata, showing clinically meaningful responses compared to placebo.

In this study, dose-response modeling predicted that once-daily abrocitinib doses of 100 mg and 200 mg may provide a clinically meaningful response in treating moderate-to-severe atopic dermatitis compared to placebo.

This study found that baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata, with similar improvements observed in both clinician-reported and patient-reported measures.

This study found that the optimized topical AR antagonist 39, derived from 14-P1, demonstrated potent AR antagonism and comparable efficacy to pyrilutamide in a hair-growth mouse model, with a faster onset and favorable safety profile.

This study reports the discovery of LX-38, a novel non-steroidal drug candidate that may offer safer treatment for conditions like Benign Prostatic Hyperplasia by avoiding hormonal side effects associated with current therapies.

This case report suggests that spironolactone may induce prostate cancer proliferation in patients on abiraterone acetate, advising against its use for managing treatment-associated side effects in these individuals.

This study found that the monophasic oral contraceptive ethinylestradiol/chlormadinone acetate was more effective in treating mild to moderate papulopustular acne in women than ethinylestradiol/levonorgestrel.

This case report describes the first known occurrence of alopecia areata associated with cemiplimab, an anti-PD1 drug, in a patient with a positive cancer treatment response.

In this study, novel substituted benzoyl benzoic acids and phenylacetic acids were potent and selective inhibitors of human steroid 5alpha-reductase type 2, with one compound showing promising bioavailability in rats for potential clinical evaluation.

This article reviews the use of cyproterone acetate for conditions like prostate cancer and sexual disorders, highlighting its effects on libido but reporting no new specific trial results.

This randomized, controlled clinical trial found that combining 25 mg/d bicalutamide with 1 mg/d minoxidil for 24 weeks did not enhance hair density improvement in female pattern hair loss compared to 1 mg/d minoxidil alone, with no significant difference observed between the groups.

In this analysis of two trials, baricitinib showed eyebrow and eyelash regrowth in severe alopecia areata patients with greater than 20% scalp hair loss at Week 36, compared to placebo.

This study found that orally administering the CCR5 inhibitor Maraviroc improved hair loss in 4 out of 5 mice with alopecia areata and also reduced the development of the condition, evidenced by decreased CCR5+ T-cell infiltration in treated mice.

Formestane is a preferred second-line treatment for advanced breast cancer in postmenopausal women because it's effective and has fewer side effects.

Cedrol promotes hair growth better than baricitinib by regulating immune cells.

In this study, a risk score was developed and validated to identify patients at high risk of clinical failure after femoropopliteal peripheral vascular intervention, aiming to guide the selection of patients who may benefit from paclitaxel-coated devices or alternative strategies.

In this study, patients with varying severities of acne, seborrhoea, and hirsutism responded differently to Cyproteronacetate and Ethinyloestradiol treatment, with improvement rates dependent on symptom severity and treatment duration.

Baricitinib helps keep hair, eyebrows, and eyelashes regrown for 3 years in most people with severe hair loss.

This study presented at the ASCO Annual Meeting reported that the epidermal growth factor receptor antibody ABX-EGF showed preliminary efficacy in renal cell cancer patients, with tolerable side effects, while bortezomib demonstrated clinical benefit in a significant proportion of multiple myeloma patients.

In this study, the researchers reported that the optimized compound 39 demonstrated potent AR antagonism and favorable pharmacokinetics in a hair-growth mouse model, achieving similar efficacy to pyrilutamide with faster onset and preserved safety, offering promise for next-generation topical AR antagonist development.

In this study, a treatment regimen combining cyproterone acetate and ethinyl estradiol significantly improved acne and seborrhoea in most women after three months, but had varied effects on hirsutism and alopecia.

Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.